Skip to main content

Table 2 Analysis of abatacept effectiveness overall, and stratified by line of therapy, and by number of previous failed anti-TNFs

From: Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

Measure Baseline Change from baseline to month 6
  N Mean (SD)   Mean (95% CI)
   Overall  
DAS28 (ESR) 539 5.5 (1.2) 473 −1.5 (−1.6, –1.3)
DAS28 (CRP) 151 5.2 (1.3) 113 −1.5 (−1.7, –1.2)
CDAI 647 31.7 (13.2) 605 −15.2 (−16.3, –14.1)
   First-line  
DAS28 (ESR) 33 5.2 (1.2) 29 −1.7 (−2.3, –1.1)
DAS28 (CRP) 5 4.5 (1.3) 4 −2.0 (−3.2, –0.8)
CDAI 48 31.9 (11.9) 41 −18.3 (−22.0, –14.6)
   Second-line  
DAS28 (ESR) 506 5.6 (1.2) 444 −1.5 (−1.6, –1.3)
DAS28 (CRP) 146 5.3 (1.3) 109 −1.4 (−1.7, –1.2)
CDAI 599 31.7 (13.2) 564 −15.0 (−16.1, –13.9)
   One previous anti-TNF  
DAS28 (ESR) 247 5.5 (1.2) 221 −1.6 (−1.8, –1.4)
DAS28 (CRP) 64 5.2 (1.3) 46 −1.7 (−2.2, –1.2)
CDAI 291 30.6 (12.7) 278 −15.0 (−16.5, –13.5)
   ≥2 previous anti-TNFs  
DAS28 (ESR) 251 5.6 (1.3) 216 −1.3 (−1.5, –1.1)
DAS28 (CRP) 78 5.3 (1.4) 59 −1.2 (−1.6, –0.8)
CDAI 295 32.5 (13.6) 275 −14.7 (−16.4, –12.9)
  1. CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; LDAS, low disease activity state; SD, standard deviation; TNF, tumor necrosis factor.